Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tests Offer Early Detection of Gastric Disorders

By LabMedica International staff writers
Posted on 02 Sep 2008
Two new diagnostic tests, GastroPanel and GastroView, when used as routine examinations in health screening as well as in the diagnosis of dyspepsia, Helicobacter pylori infection, and atrophic gastritis, can make it possible to improve the early diagnosis of the most important risk factor for gastric cancer, namely, mildly symptomatic and in most cases asymptomatic atrophic gastritis. More...


The tests also improve on patient safety. Utilization of these new developments can reduce the number of unnecessary procedures (gastroscopies) and treatments (continuous reduction of gastric acid secretion with protein pump inhibitor [PPI] therapy and/or unnecessary eradication therapy for H. pylori).

Both GastroPanel and GastroView tests were developed by Biohit (Helsinki, Finland). At the beginning of the 1980s, Australian researchers discovered that inflammation in the stomach (gastritis) as well as ulceration of stomach or duodenum (peptic ulcer disease) are the result of H. pylori infection in the stomach.

The unique, non-invasive GastroPanel examination diagnoses not only H. pylori infection, but also atrophic gastritis and its location. Atrophic gastritis causes an increase risk of gastric cancer, vitamin B12 deficiency, and peptic ulcer disease. GastroPanel also reveals if the risk of gastroesophageal reflux disease is increased, due to high stomach acid secretion. The test measures four biomarkers in blood: pepsinogen I and II, gastrin-17, and H. pylori antibodies. The GastroPanel examination and the GastroSoft software interpreting its results have been developed for use as a primary and follow-up examination in the diagnosis and treatment of patients with dyspepsia, H. pylori infection, atrophic gastritis, and related risks.

If the GastroPanel examination gives a normal result, the diagnosis is either functional dyspepsia or another disease not involving the gastric mucosa. The examination diagnoses H. pylori infection, atrophic gastritis, and its location (corpus, antrum, or both). GastroSoft interpretation software shows the test results, reference ranges, and diagnosis, and when necessary gives recommendation on possible treatment or further testing. The GastroSoft report also indicates if there is an increased risk of gastroesophageal reflux disease.

Until now, before the GastroPanel test was invented, H. pylori-related atrophic gastritis and the associated risks could only be detected with gastroscopy and biopsy specimen examination. The current "test-and-treat” method is unable to detect the disorder. This serious medical and ethical problem can be corrected simply and economically by including the GastroPanel examination as the test used in the test-and-treat strategy.

The GastroPanel test will allow practical medicine to benefit from the discovery of H. pylori even more than before, according to Biohit researchers. When combined, the two newly developed tests should promote the development of safe and ethical evidence-based therapy, particularly in outpatient care and possibly also in screening examinations.

Serologic tests that measures specific H. pylori IgG and IgA antibodies can determine if an individual has been infected and has been a commonly used test for several years. This has normally only been available from a venous blood sample (syringe sampling from a vein) taken at a hospital or a doctor's office. Biohit have now combined this test with two other extremely useful markers, pepsinogen I and pepsinogen II, in the patented Gastroview concept that is available through a single finger-prick blood sample.

Prolonged infection with H. pylori can cause a number of problems, including peptic ulcers, and changes to the gastric mucosa and atrophic gastritis, in particular. In a process of chronic gastritis of the stomach mucosa, gastric glandular cells are lost and eventually replaced by intestinal and fibrous tissues. As a result, the stomach's secretion of essential substances such as hydrochloric acid, pepsinogens, and intrinsic factor is impaired, leading to digestive problems, vitamin B12 deficiency, and megaloblastic anemia. Vitamin B12 deficiency has also been associated with dementia. This cascade effect can lead to very serious long-term implications.

The concentrations of these markers and the presence or absence of H. pylori will provide a health check on the stomach and all from a finger-prick blood sample. In addition to asymptomatic atrophic gastritis, the GastroView test also detects gastroesophageal reflux disease (GERD). Approximately one-fourth of the population suffers from this condition that puts the patient at risk of severe complications including erosive esophagitis and so-called Barrett's esophagus, which can be asymptomatic and over time, unless treated, can even progress into esophageal cancer.

The test results are provided in a comprehensive report that can be given to the individual's doctor if necessary, but in non-technical language, the combination of results from the markers tested (H. pylori, pepsinogen I, and pepsinogen II) will give a good indication of the level of atrophic gastritis in the gastric mucosa (if any). The results will also be provided with recommendations.

Scientists at Biohit recommend that the GastroPanel and GastroView examinations be used as a routine screening examination for all patients over 45, and included in the treatment practice of dyspepsia-like complaints in patients of all ages. To ensure patient safety, a GastroPanel examination or a gastroscopy is recommended before any PPI therapy and H. pylori eradication therapy. Unlike gastroscopy, GastroPanel is able to assess the recovery of the loss of the function of gastric mucosa due to atrophic gastritis and the risk of complications from GERD.

Related Links:
Biohit

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Pathology

view channel
Image: Virtual staining of label-free tissue in imaging mass spectrometry (Photo courtesy of Ozcan Lab/UCLA)

Deep Learning Advances Imaging Mass Spectrometry with Virtual Histological Detail

Imaging mass spectrometry (IMS) is a powerful technique that can map thousands of molecular species in biological tissues with exceptional chemical specificity. However, IMS is hindered by relatively low... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.